Senators grilled Robert F. Kennedy Jr. On vaccines, drug pricing, and public health policy during a contentious Senate hearing on Wednesday, marking his first appearance before Congress since September 2024. The hearing, held by the Senate Health, Education, Labor, and Pensions Committee, focused on Kennedy’s role as Secretary of Health and Human Services and his views on ongoing public health initiatives. Kennedy faced pointed questions from both Democratic and Republican senators regarding his past statements on vaccine safety and his approach to lowering prescription drug costs.
The session came amid heightened scrutiny of Kennedy’s confirmation process and his alignment with the Trump administration’s health policy agenda. As HHS Secretary, Kennedy oversees major agencies including the Centers for Disease Control and Prevention, the Food and Drug Administration, and the Centers for Medicare & Medicaid Services. His testimony followed a series of seven hearings across Capitol Hill in as many days, during which he defended his positions on emerging health threats and federal health spending.
Senators challenged Kennedy on his long-standing skepticism about certain vaccines, particularly his past claims linking vaccines to autism—a position widely rejected by the scientific community. Kennedy reiterated his support for vaccine safety research but stopped short of endorsing specific immunization schedules during the exchange. When pressed by Senator Bernie Sanders (I-VT) on whether he stood by previous remarks suggesting vaccines cause autism, Kennedy stated, “I believe in rigorous science and transparency in vaccine development,” without directly addressing the historical claim.
Drug pricing emerged as another focal point, with senators questioning Kennedy’s strategy to reduce out-of-pocket costs for Americans. Kennedy highlighted the administration’s push to expand the use of generic drugs and negotiate prices for high-cost medications under Medicare Part D. He referenced ongoing efforts to implement the Inflation Reduction Act’s drug pricing provisions, which allow Medicare to negotiate prices for certain high-expenditure drugs—a policy projected to save the federal government billions over the next decade.
The hearing too touched on public trust in health institutions, with several senators expressing concern that Kennedy’s past rhetoric could undermine confidence in federal health guidance. Kennedy responded by emphasizing his commitment to restoring transparency at HHS agencies and improving communication with the public. He cited recent initiatives to update CDC guidance on respiratory illnesses and expand access to mental health services through community health centers.
Throughout the session, Kennedy maintained a defensive yet occasionally contrite tone, acknowledging past missteps while defending his right to question established medical norms. “I have learned that public health requires humility and listening,” he said at one point, reflecting on criticism of his earlier public statements. The exchange underscored the ongoing tension between scientific consensus and alternative viewpoints in shaping national health policy.
As the Biden administration prepares to transition out of office, Kennedy’s leadership at HHS will continue to influence federal responses to infectious disease outbreaks, chronic disease prevention, and healthcare access. Observers note that his testimony may shape future legislative efforts on vaccine oversight and pharmaceutical regulation. No votes or formal actions were taken following the hearing, but the testimony is expected to inform ongoing committee deliberations.
The next scheduled appearance for Secretary Kennedy before Congress is set for May 8, 2025, when he is due to testify before the House Appropriations Subcommittee on Labor, Health and Human Services, Education, and Related Agencies regarding the president’s fiscal year 2026 budget request for HHS.
For updates on HHS policy initiatives, congressional hearings, and public health guidance, readers can visit the official websites of the U.S. Department of Health and Human Services and Senate Assist Committee.
We welcome your thoughts on this developing story. Share your perspective in the comments below and help foster an informed discussion on the future of American health policy.